BofA raised the firm’s price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees “some ...

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on HUTCHMED (HCM – Research Report), with a ...

Hutchmed has agreed to divest its share of a Chinese joint venture company through a pair of deals that will give it a cash injection of around $608 million. The deal will see Hutchmed sell its 45 ...

AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a treatment of patients with a form of non-small cell lung cancer. The approval by the ...

Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...

After hours: February 7 at 4:00:10 PM EST Loading Chart for HCM ...

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Says its lung cancer treatment Orpathys has received full approval in China for adult patients. It has been developed in collaboration ...

At close: 7 February at 16:00:01 GMT-5 ...